Incyte Corporation (INCY) outlined plans to sustain double-digit revenue growth through 2030 and accelerate its oncology ambitions, projecting core business revenue — excluding Jakafi — to reach between $3 billion and $4 billion by the end of the decade.
Speaking at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, CEO Bill Meury emphasized that the company’s current trajectory “sets the floor” for Incyte. After 2029, he added, the firm expects a five-year compound annual growth rate of 15% to 20%, fueled largely by pipeline expansion.
The overall unadjusted peak sales potential across Incyte’s pipeline was estimated at $8 billion to $10 billion. Among the most significant near-term bets is povorcitinib, a multi-cytokine inhibitor targeting hidradenitis suppurativa (HS), with an FDA approval goal set for the first quarter of 2027. Follow-on indications for vitiligo and pyoderma gangrenosum are expected roughly a year later, and peak sales for povorcitinib alone are projected at no less than $1 billion.
In oncology, Meury said Incyte is positioned to build an internal vertical “as relevant and as big as our hematology business.” The G12D inhibitor program — targeting KRAS G12D-mutated pancreatic ductal adenocarcinoma and colorectal cancer — sits squarely in that strategy. The mutation accounts for roughly 40% of PDAC cases and about 15% of CRC cases. The U.S. addressable market for these indications is estimated at $7.5 billion to $10 billion, and the frontline Phase III study aims to enroll across more than 150 sites globally.
In myeloproliferative neoplasms, the CALR-targeted monoclonal antibody INCA33989 is being developed for the roughly 20,000-patient CALR-mutated population — those with essential thrombocythemia or myelofibrosis — which represents a market north of $5 billion. For ET, an on-body delivery device is planned within six months of approval, shifting dosing from daily hydroxyurea to twice-monthly administration. Meury characterized the current standard of care as merely treating symptoms “like you treat a fever with Tylenol,” predicting a shift toward disease modification.
Regulatory pathway updates for the INCA33989 portfolio are expected on the company’s third-quarter earnings call, with monotherapy and combination data from approximately 50 to 60 patients anticipated at year-end on the ASH circuit. T-cell engager data and V617F inhibitor options are both expected in 2027.
Data from Incyte’s TGF-beta by PD-1 bispecific program will appear at ESMO, featuring a dataset of more than 40 patients. Additional tumor-type data across ovarian, head and neck, and lung cancers is expected in the first half of 2025. Phase I results at doses up to 900 milligrams showed mostly PD-1-related side effects with minimal TGF-beta toxicity. In late-line microsatellite-stable colorectal cancer, the program demonstrated a 15% response rate — compared with 0% for anti-PD-1 monotherapy — with more than half of responders harboring liver metastases.
Elsewhere in the pipeline, VGA039 (latarcibart), a Protein S modulator for von Willebrand disease, targets 7,000 to 10,000 severe frequent bleeders. Phase III data is expected in the first half of 2029.
Incyte’s stock has delivered a 45% return over the past year and was trading near its 52-week high of $132.60 during the report period.
The conference was moderated by Wells Fargo senior biotech analyst Derek Archila. Co-development partners Revolution Medicines and Prelude were also referenced in connection with the G12D program.
